Article History
Accepted: 4 September 2023
First Online: 29 September 2023
Declarations
:
: AVR was involved in the baricitinib study and is the corresponding author of the manuscript. AVR has received speaker fees/honoraria/consulting fees from Abbvie, Astra Zeneca, Eli Lilly, Pfizer, Roche, Novartis, UCB and SOBI.
: This work was supported in parts by grants from the NIHR (CC).
: The nature of the work did not require any ethical approval.
: Not applicable.
: Not applicable.
: No additional data is available for this manuscript.
: NKB: concept, design, literature review, drafting and editing of the manuscript. CC: concept, literature review, drafting and editing of the manuscript. AVR: concept, design, reviewed the draft for intellectual comments. All authors approved the final version of the draft.
: None.